Merit Medical Raises 2026 Earnings Outlook To $4.33-$4.37 A Share And Buys Heart-Pacing Startup Solo Pace
Third-quarter revenue rose 8.4% to $416.2 million, and the company paid about $45 million for the rest of Solo Pace.
Merit Medical Systems, which makes catheters, stents and other devices for cardiology, radiology, oncology, critical care and endoscopy, said third-quarter results beat the high end of its own expectations and lifted its full-year adjusted earnings guidance to $4.33 to $4.37 a share, up from $4.25 to $4.35. The company also said Thursday it paid about $45 million to buy the rest of Solo Pace, a heart-pacing company it already part-owned.
A quarter that beat management's own bar
Revenue came in at $416.2 million, up 8.4% as reported. Constant-currency revenue rose 8%, and organic constant-currency growth, which strips out acquisitions and the divested DualCap line, was 9%. CEO Martha Aronson said the U.S. grew strongly and demand ran better than expected across both the Foundational and Therapeutic platforms.
Profit grew faster than sales. Net income under standard accounting was $42.3 million, or $0.70 a share, against $27.8 million, or $0.46, a year earlier. Adjusted earnings per share rose 22% to $1.12, and adjusted operating margin reached 21.3%, from 19.7%.
The Therapeutic group grew 14% to $140.5 million, led by endoscopy, up 33%, and oncology, up 16%. Procedural Solutions fell 16%. Adjusted gross margin slipped to 52.8% from 53.6%.
Guidance moves up, revenue range tightens
Revenue guidance for 2026 is now $1.635 billion to $1.642 billion, from $1.631 billion to $1.643 billion. The low end rose and the high end fell. The earnings range lifted at both ends.
Merit held $503.6 million of cash at September 30 against $747.5 million of total debt. Cash from operations was $175.2 million for the first nine months, down from $198.9 million a year earlier. Free cash flow was $129.5 million, against $141.6 million.
Aronson said Merit is also finalizing a longer-term strategic plan while pursuing its Continued Growth Initiative targets for the period ending December 31, 2026. The investor call was set for 4:30 p.m. ET Thursday.
Buying the rest of Solo Pace
Merit paid about $45 million on October 13 for all remaining equity of Solo Pace, which makes temporary pacing systems for transcatheter aortic valve replacement procedures. Merit already owned about 18% after paying a total of $5 million and had been the exclusive distributor of the products.
The company projects the deal will be immaterial to 2026 results and slightly accretive to adjusted earnings per share in 2027, a forecast that includes about $1.5 million of lower interest income on cash used. It expects the deal to be slightly dilutive to standard-accounting earnings in 2027 and accretive after that.
Aronson said the company has seen a favorable response from clinicians through the distribution deal and plans to use its sales and physician education to expand adoption in the U.S.
Sources
- 8-K Filing — MERIT MEDICAL SYSTEMS INC (MMSI) — SEC EDGAR
- Exhibit mmsi-ex99d1.htm — MERIT MEDICAL SYSTEMS INC 8-K exhibit — SEC EDGAR
- Exhibit mmsi-ex99d2.htm — MERIT MEDICAL SYSTEMS INC 8-K exhibit — SEC EDGAR
- Exhibit mmsi-ex99d3.htm — MERIT MEDICAL SYSTEMS INC 8-K exhibit — SEC EDGAR
- Merit Medical Reports Third Quarter 2026 Results: Delivers — globenewswire.com